NVS240621P95000
- 0.05
- 0.000.00%
Novartis AG Newsroom
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Exsilio Therapeutics Launches With $82 Million Series A Financing to Develop Redosable Genomic Medicines for A Broad Range of Diseases
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Nestle Carefully Targets Weight-Loss Drug Users With New Food Line
German Drug Developer Evotec Seeks Adviser Input As Takeover Concerns Mount
What's Going On With Neurological Disease Focused Trevena On Thursday?
Here's Why Novartis (NVS) Is a Strong Momentum Stock
MorphoSys Set to Delist Following Acquisition by Novartis
MorphoSys Delisting From Frankfurt Stock Exchange, Nasdaq Expected to Take Place in 3Q
Novartis Delisting Offer Is In Line With Price of Acquisition Closed in May
Novartis to Offer EUR68 a Share in Cash to Minority MorphoSys Shareholders
Novartis Holds Around 91.04% of MorphoSys as of Thursday
Novartis to Start Squeeze-Out of MorphoSys' Minority Shareholders
Express News | China Council for the Promotion of International Trade Chairman REN Hongbin conducted research at Roche Group and Novartis.
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Stifel Starts Celldex at Buy, Sees Lead Drug as Potential Blockbuster
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
U.S. Drug Shortages Worsen to Reach a Decade High: Report
EU to Require Additional Cancer Risk Labeling on CAR T Therapies
Express News | Novartis' Lusutinib phosphate tablets have been approved for a new indication in China for the treatment of chronic graft-versus-host disease.